TORONTO, April 27, 2017 /CNW/ - SQI Diagnostics Inc. ("SQI"
or the "Company") (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes
proprietary technologies and products for advanced microarray diagnostics will be presenting on Monday May
1 st at the Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel,
Toronto, Ontario.
"We are pleased to be presenting again this year at this key healthcare industry conference," said Andrew Morris, CEO of SQI Diagnostics. "This conference gives us the opportunity to share with the investment
community the significant progress made in the past year with our biopharma and diagnostic
customers."
Please join us for our company presentation on May 1, 2017 at 10:30am.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and
products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed
to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more
information, please visit www.sqidiagnostics.com.
Contacts:
Investor Relations Contact:
Andrew Morris
Chief Executive Officer
416.674.9500 ext. 229
amorris@sqidiagnostics.com
Patricia Lie
Vice President of Finance and Administration
416.674.9500 ext. 277
plie@sqidiagnostics.com
Forward-looking Information
This news release contains certain forward-looking statements, including, without limitation, statements containing the
words "will", "may", "expects", "intends", "anticipates" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current
expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ
materially from those anticipated. The forward-looking statements in this news release include without limitation, statements
with respect to the Private Placement and the use of proceeds of the Private Placement. These forward-looking statements involve
risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory and stock
exchange approvals, general economic and market segment conditions, and international risk and currency exchange risks,
agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent
to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for
our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment
conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from
time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at
www.sedar.com. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to
publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise,
except as required by applicable laws.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the
securities in the United States. The securities have not been and will not be registered under
the U.S. Securities Act or any state securities laws and may not be offered or sold within the United
States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an
exemption from such registration is available.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE SQI Diagnostics Inc.
View original content: http://www.newswire.ca/en/releases/archive/April2017/27/c8821.html